ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

165
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
20 Nov 2023 22:45Broker

Pharma Sector: Q2FY24 Review

In Q2FY24, the Pharma Coverage universe posted robust revenue growth of 14.3%/1.7% YoY/QoQ on account of volume rampup, new launches (especially...

Logo
304 Views
Share
02 Nov 2023 06:55Broker

Axis Top Picks - ‘Growth at a Reasonable Price’ – an Overarching Theme - Nov 2023

We are proud to share that our Axis Top Picks basket delivered impressive returns of 25% in the last one year, beating the benchmark Nifty 50 index

Logo
213 Views
Share
12 Oct 2023 08:33Broker

Pharma - Q2FY24 - Earnings Preview

The Pharma companies under our coverage are likely to report aggregate Revenue/EBITDA/PAT growth of 17.4%/23.8%/25.2% YoY in Q2FY24E.

Logo
279 Views
Share
05 Oct 2023 07:59Broker

Axis Top Picks - Oct 2023

We are proud to share that our Axis Top Picks basket delivered impressive returns of 32% in the last one year, beating by a wide margin the 15%...

Logo
560 Views
Share
04 Sep 2023 23:52Broker

Axis Research Scorecard Report - August 2023

We are proud to share that we released several Top Sector Ideas during the month and we highly encourage you to refer to these exclusive reports

Logo
313 Views
Share
x